Preexposure prophylaxis for the prevention of HIV infection – 2014 : a clinical practice guideline

Details

• Corporate Authors:
  United States. Public Health Service. ; Centers for Disease Control and Prevention (U.S.) ; National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.)
• Description:
  This publication provides a comprehensive clinical practice guideline for the use of PrEP for the prevention of HIV infection in the United States. It incorporates and extends information provided in interim guidance for PrEP use with MSM, with heterosexually active adults, and with IDU (also called persons who injection drugs [PWID]). Currently, prescribing daily oral PrEP with TDF/FTC is recommended as one prevention option for MSM, heterosexual men, heterosexual women, and IDU at substantial risk of HIV acquisition. As the results of additional PrEP clinical trials and studies in these and other populations at risk of HIV acquisition become known, this guideline will be updated.
• Subjects:
  Anti-HIV Agents/therapeutic Use HIV Infections/epidemiology HIV Infections/prevention & Control Homosexuality, Male Pre-Exposure Prophylaxis Pregnancy Pregnancy Complications, Infectious/prevention & Control Truvada
• Document Type:
  Text
• Genre:
  Practice Guideline
• Place as Subject:
  United States
• Pages in Document:
  67 numbered pages
• Collection(s):
  Guidelines and Recommendations
• Main Document Checksum:
  urn:sha-512:5532509b918eaa40d6399016048b9cc096b0c4bb43d762fbbf4224e49b1738f60d32f1e27b00871546c94630c09eefe04ea083fb79f397755eea8ddef74d13f4
• Download URL:
  https://stacks.cdc.gov/view/cdc/79935/cdc_79935_DS1.pdf
• File Type:
  [PDF - 791.62 KB ]